Target Dose Range Identification for Buprenorphine/Naloxone Combination Tablet in Low to Moderate Opiate Dependence
Data Collection
Narcotic-Related Disorders+2
+ Mental Disorders
+ Opioid-Related Disorders
Treatment Study
Summary
Study start date: August 1, 1995
Actual date on which the first participant was enrolled.This study focuses on finding the right dose range of a medication called buprenorphine/naloxone combination tablet that can help individuals with low to moderate opiate addiction. The goal is to provide relief without causing dependence. The study is important as it aims to find an appropriate starting dose for treatment, potentially improving care for those struggling with opiate addiction. Participants in this study will receive the buprenorphine/naloxone combination tablet. The study measures the effectiveness of the treatment by evaluating opiate cravings, opiate use, and withdrawal symptoms. The aim is to find a balance where the medication reduces cravings and withdrawal symptoms without leading to further dependence.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 21 to 50 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location